California Pacific Medical Center Research Institute, San Francisco Coordinating Center, California.
Department of Medicine, Marcus Institute for Aging Research, Hebrew SeniorLife, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
J Gerontol A Biol Sci Med Sci. 2020 Jun 18;75(7):1317-1323. doi: 10.1093/gerona/glz081.
Lack of consensus on how to diagnose sarcopenia has limited the ability to diagnose this condition and hindered drug development. The Sarcopenia Definitions and Outcomes Consortium (SDOC) was formed to develop evidence-based diagnostic cut points for lean mass and/or muscle strength that identify people at increased risk of mobility disability. We describe here the proceedings of a meeting of SDOC and other experts to discuss strategic considerations in the development of evidence-based sarcopenia definition.
Presentations and panel discussions reviewed the usefulness of sarcopenia as a biomarker, the analytical approach used by SDOC to establish cut points, and preliminary findings, and provided strategic direction to develop an evidence-based definition of sarcopenia.
The SDOC assembled data from eight epidemiological cohorts consisting of 18,831 participants, clinical populations from 10 randomized trials and observational studies, and 2 nationally representative cohorts. In preliminary assessments, grip strength or grip strength divided by body mass index was identified as discriminators of risk for mobility disability (walking speed <0.8 m/s), whereas dual-energy X-ray absorptiometry-derived lean mass measures were not good discriminators of mobility disability. Candidate definitions based on grip strength variables were associated with increased risk of mortality, falls, mobility disability, and instrumental activities of daily living disability. The prevalence of low grip strength increased with age. The attendees recommended the establishment of an International Expert Panel to review a series of position statements on sarcopenia definition that are informed by the findings of the SDOC analyses and synthesis of literature.
International consensus on an evidence-based definition of sarcopenia is needed. Grip strength-absolute or adjusted for body mass index-is an important discriminator of mobility disability and other endpoints. Additional research is needed to develop a predictive risk model that takes into account sarcopenia components as well as age, sex, race, and comorbidities.
由于缺乏共识,如何诊断肌肉减少症限制了诊断这种疾病的能力,并阻碍了药物的开发。肌少症定义和结局联合会(SDOC)成立的目的是为瘦体重和/或肌肉力量制定基于证据的诊断切点,以确定那些有更高移动性残疾风险的人群。在这里,我们描述了 SDOC 及其它专家会议的议事程序,讨论了制定基于证据的肌少症定义的战略考虑因素。
会议展示和小组讨论回顾了肌少症作为生物标志物的有用性、SDOC 用于建立切点的分析方法以及初步研究结果,并为制定基于证据的肌少症定义提供了战略指导。
SDOC 汇集了来自八个流行病学队列的数据,这些队列共包括 18831 名参与者,以及来自 10 项随机试验和观察性研究的临床人群和两个全国代表性队列的数据。在初步评估中,握力或握力除以体重指数被确定为移动性残疾(行走速度<0.8 m/s)风险的判别指标,而双能 X 线吸收法测定的瘦体重测量值不是移动性残疾的良好判别指标。基于握力变量的候选定义与死亡率、跌倒、移动性残疾和日常生活活动能力残疾的风险增加有关。低握力的患病率随着年龄的增长而增加。与会者建议成立一个国际专家小组,审查一系列关于肌少症定义的立场声明,这些声明是基于 SDOC 分析和文献综述的结果。
需要国际上对基于证据的肌少症定义达成共识。握力-绝对或按体重指数调整-是移动性残疾和其他终点的重要判别指标。需要进一步研究来开发一种预测风险模型,该模型将肌少症成分以及年龄、性别、种族和合并症考虑在内。